HC Wainwright Has Optimistic Opinion of RAPP FY2026 Earnings

Key Points

• HC Wainwright raised its earnings forecasts, projecting a FY2026 loss of $3.18 per share, versus its prior estimate of $4.51, and narrowing projected losses in later years. It maintained its Buy rating and $66 price target; the company is still expected to remain loss-making.
• Rapport reported a quarterly loss of $0.84 per share, beating analyst expectations of a $1.20 loss by $0.36.
• Company insiders bought about 1.03 million shares worth $22 million over the past three months, while selling about 75,000 shares.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) - Equities researchers at HC Wainwright increased their FY2026 earnings estimates for Rapport Therapeutics in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($3.18) per share for the year, up from their prior forecast of ($4.51). HC Wainwright currently has a "Buy" rating and a $66.00 target price on the stock. The consensus estimate for Rapport Therapeutics' current full-year earnings is ($3.34) per share. HC Wainwright also issued estimates for Rapport Therapeutics' Q4 2026 earnings at ($0.72) EPS, Q1 2027 earnings at ($0.91) EPS, Q2 2027 earnings at ($1.06) EPS, Q3 2027 earnings at ($1.12) EPS, Q4 2027 earnings at ($1.19) EPS, FY2027 earnings at ($4.29) EPS, FY2028 earnings at ($5.37) EPS, FY2029 earnings at ($5.56) EPS and FY2030 earnings at ($4.58) EPS.

Other analysts have also recently issued research reports about the company. Wells Fargo & Company reduced their price objective on Rapport Therapeutics from $50.00 to $47.00 and set an "overweight" rating for the company in a research report on Thursday. TD Cowen reissued a "buy" rating on shares of Rapport Therapeutics in a research report on Tuesday, October 20th. BTIG Research boosted their price target on Rapport Therapeutics from $75.00 to $89.00 and gave the company a "buy" rating in a research note on Tuesday, October 20th. Raymond James Financial set a $73.00 price target on Rapport Therapeutics in a research note on Wednesday. Finally, William Blair began coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an "outperform" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $64.50.

Rapport Therapeutics Stock Performance

NASDAQ:RAPP opened at $24.44 on Monday. Rapport Therapeutics has a 12 month low of $22.06 and a 12 month high of $52.93. The company has a market cap of $1.45 billion, a PE ratio of -7.71 and a beta of 1.40. The company has a 50 day simple moving average of $34.16 and a two-hundred day simple moving average of $35.53.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.84) earnings per share for the quarter, beating analysts' consensus estimates of ($1.20) by $0.36.

Insider Buying and Selling at Rapport Therapeutics

In other news, Director James Healy acquired 969,480 shares of Rapport Therapeutics stock in a transaction dated Wednesday, October 28th. The stock was purchased at an average cost of $21.00 per share, with a total value of $20,359,080.00. Following the completion of the purchase, the director directly owned 2,815,707 shares in the company, valued at approximately $59,129,847. This trade represents a 52.51% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven M. Paul acquired 35,714 shares of the firm's stock in a transaction dated Thursday, October 22nd. The shares were purchased at an average price of $27.28 per share, for a total transaction of $974,277.92. Following the completion of the transaction, the director directly owned 77,380 shares in the company, valued at approximately $2,110,926.40. This trade represents a 85.71% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 1,031,174 shares of company stock valued at $22,023,898 and have sold 75,435 shares valued at $3,348,983. Company insiders own 12.48% of the company's stock.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its holdings in shares of Rapport Therapeutics by 13.8% in the third quarter. Russell Investments Group Ltd. now owns 63,138 shares of the company's stock worth $2,121,000 after buying an additional 7,680 shares in the last quarter. Alps Advisors Inc. boosted its holdings in shares of Rapport Therapeutics by 31.8% during the 3rd quarter. Alps Advisors Inc. now owns 63,565 shares of the company's stock valued at $2,136,000 after purchasing an additional 15,322 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Rapport Therapeutics during the 3rd quarter valued at about $82,000. Profund Advisors LLC boosted its holdings in shares of Rapport Therapeutics by 420.8% during the 3rd quarter. Profund Advisors LLC now owns 33,112 shares of the company's stock valued at $1,113,000 after purchasing an additional 26,754 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Rapport Therapeutics by 40.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 15,154 shares of the company's stock valued at $500,000 after purchasing an additional 4,342 shares in the last quarter.

Rapport Therapeutics News Roundup

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: HC Wainwright now forecasts FY2026 EPS of -$3.18, compared with its prior estimate of -$4.51, and FY2027 EPS of -$4.29, versus -$6.80 previously. Its estimates for FY2028, FY2029, and FY2030 were also revised to narrower losses. MarketBeat report
• Positive Sentiment: The analyst also lowered projected losses for each quarter from Q4 2026 through Q4 2027, while maintaining its $66 price target and Buy rating. MarketBeat report
• Neutral Sentiment: Despite the upgrades, HC Wainwright still expects Rapport to report losses in the periods cited; its revisions are improved forecasts, not a return to profitability.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.